< Back to previous page
Researcher
Patrik Verstreken
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Behavioural neuroscience
- Disciplines (KU Leuven):Neurological and neuromuscular diseases
- See also: Patrik Verstreken (Flanders Institute for Biotechnology)
Affiliations
- Research Group Molecular Neurobiology (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2017 → Today - Laboratory of Neuronal Communication (VIB-KU Leuven) (Lab)
Responsible
From1 Jan 2008 → Today - Laboratory of Neuronal Communication (VIB-KU Leuven) (Lab)
Member
From1 Jan 2017 → Today - VIB-KU Leuven Center for Brain & Disease Research (Research Center)
Responsible
From1 Jan 2017 → Today - Verstreken Lab (Research group)
Responsible
From1 Jan 2017 → Today - Department of Human Genetics (Department)
Member
From1 Apr 2009 → 31 Dec 2016
Projects
1 - 10 of 54
- The Role of Parkinsonism genes in synaptic autophagyFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Tau-dependent synaptic remodeling in health and diseaseFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Translational Markers for Precision Medicine in Modifying Parkinson's DiseaseFrom1 Feb 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Investigating cell type specific defects in protein quality control across the genetic landscape of Parkinson’s diseaseFrom1 Oct 2022 → TodayFunding: FWO junior postdoctoral fellowship
- When size matters: a platform to study molecular interactions and multimerisationFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- Dissecting the genetic interactions controlling α-Synuclein accumulation in Parkinson’s DiseaseFrom15 Mar 2022 → TodayFunding: FWO fellowships
- Analyzing the regulation of synaptic vesicle mobility by pre-synaptic liquid phase-separation in health and diseaseFrom7 Mar 2022 → TodayFunding: FWO fellowships
- Therapeutic targeting of pathogenic presynaptic Tau in human neurons in a chimeric Alzheimer’s Disease mouse modelFrom24 Jan 2022 → TodayFunding: FWO Strategic Basic Research Grant
- Investigating cell type specific defects in protein quality control across the genetic landscape of Parkinson’s disease.From1 Oct 2021 → 30 Sep 2022Funding: BOF - postdoctoral mandates
- Resilience and vulnerability in the cellular phase of Alzheimer’s disease.From1 Oct 2021 → TodayFunding: BOF - Methusalem
Publications
1 - 10 of 146
- Neuronal identity defines a-synuclein and tau toxicity(2023)
Authors: Roman Praschberger, Natalie Kaempf, Eliana Nachman, Stein Aerts, Patrik Verstreken
- EndophilinA-dependent coupling between activity-induced calcium influx and synaptic autophagy is disrupted by a Parkinson-risk mutation(2023)
Authors: Marianna Decet, Lily Karamanou, Nikolaos Louros, Tassos Economou, Frederic Rousseau, Joost Schymkowitz, Patrik Verstreken
Pages: 1402 - + - Neurodegeneration cell per cell(2023)
Authors: Sriram Balusu, Bart De Strooper, Patrik Verstreken
Pages: 767 - 786 - Tyrosyl-tRNA synthetase has a noncanonical function in actin bundling(2023)
Authors: Patrick Callaerts, Patrik Verstreken
- Parkinsonism mutations in DNAJC6 cause lipid defects and neurodegeneration that are rescued by Synj1(2023)
Authors: Patrik Verstreken
- A reference human induced pluripotent stem cell line for collaborative studies(2022)
Authors: Patrik Verstreken
Pages: 1685 - + - Tau, synapses and brain disease(2022)
Authors: Pablo Largo Barrientos, Patrik Verstreken, Valerie Uytterhoeven
- Nano-positioning and tubulin conformation contribute to axonal transport regulation of mitochondria along microtubules(2022)
Authors: Marianna Decet, Tobie Martens, Patrik Verstreken, Pieter Vanden Berghe
- Do we still need animals? Surveying the role of animal-free models in Alzheimer's and Parkinson's disease research(2022)
Authors: Bart De Strooper, Patrik Verstreken
- Synaptic proteostasis in Parkinson's disease(2022)
Authors: Eliana Nachman, Patrik Verstreken
Pages: 72 - 79
Patents
1 - 10 of 10
- Screening method for synaptogyrin-3 inhibitors (Inventor)
- Targeting synaptogyrin-3 in tauopathy treatment (Inventor)
- Targeting synaptogyrin-3 in tauopathy treatment (Inventor)
- Means and methods for treatment of early-onset parkinson's disease (Inventor)
- Means and methods for treatment of early-onset parkinson's disease (Inventor)
- Compounds for treatment of intractable epilepsy and doors syndrome (Inventor)
- Targeting synaptogyrin-3 in tauopathy treatment (Inventor)
- Compounds for treatment of intractable epilepsy and doors syndrome (Inventor)
- Restoring phosphorylation of a novel pink1 substrate to treat parkinson's disease (Inventor)
- Restoring phosphorylation of a novel pink1 substrate to treat parkinson's disease (Inventor)